gefitinib has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Trials (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Recent Studies (post-2010) (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,473 | 3 | 1,057 |
| Protein | Taxonomy | gefitinib (IC50) | benzyloxycarbonylleucyl-leucyl-leucine aldehyde (IC50) |
|---|---|---|---|
| Proteasome subunit beta type-11 | Homo sapiens (human) | 1.9893 | |
| Calpain-9 | Homo sapiens (human) | 9.88 | |
| Proteasome subunit alpha type-7 | Homo sapiens (human) | 1.9893 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 3.9 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.8999 | |
| Aromatase | Homo sapiens (human) | 0.044 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 0.5 | |
| Proteasome subunit beta type-1 | Homo sapiens (human) | 1.0853 | |
| Proteasome subunit alpha type-1 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-2 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-3 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-4 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-8 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-9 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-5 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-4 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-6 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-5 | Homo sapiens (human) | 0.6088 | |
| Proteasome subunit beta type-10 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-3 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-2 | Homo sapiens (human) | 2.0443 | |
| Proteasome subunit alpha type-6 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha-type 8 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-7 | Homo sapiens (human) | 1.9893 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, RT; Hua, C; Lv, XX; Ma, HR; Yu, JJ; Zheng, XY | 1 |
1 other study(ies) available for gefitinib and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Leupeptins; Macrolides; Male; Mice; Mouth Neoplasms; Mutagenesis; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein Stability; Proteolysis; SOXB1 Transcription Factors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2020 |